L

Lite Strategy Inc.
D

LITS

0.98040
USD
-0.03
(-2.93%)
مغلق
حجم التداول
4,262
الربح لكل سهم
-15
العائد الربحي
-
P/E
-0
حجم السوق
33,358,306
المقالات
المزيد

العنوان: Lite Strategy Inc.

القطاع: الرعاية الصحية
الصناعة: Biotechnology
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily,selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.